EU External Trade - Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other, containing antibiotics

Extra-EU sourcing of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other, containing antibiotics is highly concentrated. 🇯🇵 Japan captures 57.8% of imports (€254.8M), followed by 🇨🇳 China (22.0%). With an HHI of 4103, this Concentrated market exposes the EU to supply dependency risks.

European exports of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other, containing antibiotics are concentrated on a few markets. 🇨🇭 Switzerland accounts for 68.1% (€443.6M), ahead of 🇺🇸 United States (17.2%). The top three destinations are 🇨🇭 Switzerland, 🇺🇸 United States, 🇯🇴 Jordan.

Within the EU, 🇳🇱 Netherlands concentrates 70.0% of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale, Other, containing antibiotics imports, well ahead of 🇪🇸 Spain (9.6%). The top importing member states are 🇳🇱 Netherlands, 🇪🇸 Spain, 🇩🇪 Germany.

In 2025, trade flows diverged: imports were surging (121.9%) while exports were falling sharply (-25.2%), signalling a structural market shift.